Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Seniors - 65 +
  • New York
  • Staten Island


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure
    NCT03035474
    Condition:   Heart Failure
    Interventions:   Other: Digital Engagement;   Other: Direct Engagement
    Sponsors:   Duke University;   Duke Clinical Research Institute
    Recruiting
  • Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
    NCT04044664
    Condition:   Post-Traumatic Stress Disorder
    Interventions:   Drug: Placebo oral capsule;   Drug: NYX-783
    Sponsors:   Aptinyx;   Premier Research Group plc;   Massachusetts General Hospital
    Recruiting
  • A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
    NCT03887715
    Condition:   Treatment Resistant Depression
    Intervention:   Device: Vagus Nerve Stimulation (VNS)
    Sponsor:   LivaNova
    Recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
    NCT03662204
    Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)
    NCT03228823
    Conditions:   Ventricular Premature Beats, Contractions, or Systoles;   Cardiomyopathies
    Interventions:   Procedure: Radiofrequency ablation;   Drug: Amiodarone (Antiarrhythmic drug)
    Sponsors:   Hunter Holmes Mcguire Veteran Affairs Medical Center;   Virginia Commonwealth University;   University of California, San Francisco;   University of Calgary;   Washington University School of Medicine;   Wake Forest University Health Sciences;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
    NCT03504917
    Condition:   Autism Spectrum Disorder
    Interventions:   Drug: Balovaptan;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
    NCT03486938
    Conditions:   Mild Cognitive Impairment;   Prodromal Alzheimer's Disease
    Interventions:   Drug: Placebo Oral Tablet;   Drug: AGB101 220 mg tablet
    Sponsors:   AgeneBio;   National Institute on Aging (NIA)
    Recruiting
  • Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome
    NCT03473223
    Condition:   Acute Coronary Syndrome
    Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
    Sponsor:   CSL Behring
    Recruiting
  • Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
    NCT03443973
    Condition:   Alzheimer's Disease
    Interventions:   Drug: Gantenerumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
    NCT03414970
    Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
    Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting
  • Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
    NCT03403751
    Conditions:   Acute Kidney Injury;   Peritonitis;   Necrotizing Soft Tissue Infection
    Interventions:   Drug: Reltecimod;   Drug: 0.9% Sodium Chloride Injection
    Sponsor:   Atox Bio Ltd
    Recruiting
  • Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
    NCT03373045
    Condition:   Asthma
    Intervention:  
    Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
    NCT03345849
    Condition:   Crohn's Disease
    Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
    NCT03345836
    Condition:   Crohn's Disease
    Interventions:   Other: Matching placebo for upadacitinib;   Drug: upadacitinib
    Sponsor:   AbbVie
    Recruiting
  • BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder
    NCT03299166
    Condition:   Obsessive-Compulsive Disorder
    Interventions:   Drug: BHV-4157;   Drug: Placebo
    Sponsor:   Biohaven Pharmaceuticals, Inc.
    Recruiting
  • Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)
    NCT03250247
    Conditions:   Deep Vein Thrombosis;   Venous Stasis;   Venous Insufficiency;   Venous Leg Ulcer;   Venous Reflux;   Post Thrombotic Syndrome
    Intervention:   Device: Stents
    Sponsors:   Washington University School of Medicine;   Ontario Clinical Oncology Group (OCOG) - McMaster University;   VasCore - Massachusetts General Hospital;   Mid America Heart Institute - St. Luke's Hospital
    Recruiting
  • A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression
    NCT03044249
    Conditions:   Psychosis;   Dementia;   Aggression;   Agitation;   Alzheimer Dementia
    Interventions:   Drug: MP-101;   Drug: Placebo
    Sponsor:   Mediti Pharma Inc.
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation
    NCT02928497
    Condition:   Stroke
    Interventions:   Device: WATCHMAN LAAC Device Implant;   Drug: Single Antiplatelet Therapy or No Therapy (Control)
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
    NCT02927249
    Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting
  • TARGET Post-Approval Study
    NCT02800863
    Condition:   Complex Regional Pain Syndrome (CRPS)
    Interventions:   Device: Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System);   Device: Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
    NCT02782104
    Condition:   Depressive Disorder, Treatment-Resistant
    Intervention:   Drug: Esketamine Nasal Spray
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer
    NCT02635009
    Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Limited Stage Small Cell Lung Carcinoma
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Other: Cognitive Assessment;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
    Recruiting
  • Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression
    NCT02600507
    Condition:   Bipolar Depression
    Interventions:   Drug: ITI-007;   Drug: Placebo
    Sponsor:   Intra-Cellular Therapies, Inc.
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
    NCT02446132
    Condition:   Agitation in Patients With Dementia of the Alzheimer's Type
    Intervention:   Drug: AVP-786
    Sponsor:   Avanir Pharmaceuticals
    Recruiting
  • Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
    NCT02194738
    Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Resectable Lung Non-Small Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
    NCT02193282
    Conditions:   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia
    NCT02060630
    Condition:   Critical Limb Ischemia
    Interventions:   Procedure: Open surgical revascularization;   Device: Endovascular revascularization
    Sponsors:   New England Research Institutes;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Boston Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Psoriasis Longitudinal Assessment and Registry (PSOLAR)
    NCT00508547
    Conditions:   Psoriasis;   Arthritis, Psoriatic
    Interventions:   Biological: Ustekinumab;   Biological: Biological therapies other than infliximab, ustekinumab and guselkumab;   Drug: Conventional systemic agents;   Biological: Infliximab;   Biological: Guselkumab
    Sponsor:   Janssen Scientific Affairs, LLC
    Recruiting
  • Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
    NCT03684044
    Condition:   Influenza
    Interventions:   Drug: Baloxavir Marboxil;   Other: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03653026
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
    NCT03503318
    Condition:   Schizophrenia
    Interventions:   Drug: TV-46000 - A;   Drug: TV-46000 - B;   Drug: Placebo
    Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT02819635
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
    Sponsor:   AbbVie
    Recruiting
  • A Registry for Patients With Chronic Hypoparathyroidism
    NCT01922440
    Condition:   Chronic Hypoparathyroidism
    Intervention:   Drug: Combination product (Natpara) and drug or supplements [Disease and drug registry]
    Sponsor:   Shire
    Recruiting
  • Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
    NCT01442194
    Condition:   Multiple Sclerosis
    Interventions:   Drug: other disease-modifying therapy;   Drug: Fingolimod
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Web Based Orthopaedic Sports Medicine Registry
    NCT01191151
    Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
    Intervention:  
    Sponsor:   Arthrex, Inc.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC